Lasa Supergenerics promoter reports no new encumbrance in FY26

Omkar Herlekar, a promoter of Lasa Supergenerics Limited , has confirmed that he did not create any encumbrance on shares during the financial year ended March 31, 2026. The declaration, submitted to the stock exchanges on April 7, 2026, states that no shares were pledged directly or indirectly during FY26 other than those already disclosed in previous financial years. This status indicates stability in the promoter's holding structure regarding pledged collateral during the reported period.

The disclosure was filed in compliance with Regulation 31(4) and (5) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. These regulations mandate promoters to provide an annual declaration regarding the encumbrance of their shareholdings. The filing was addressed to the Corporate Services Departments of BSE Limited and National Stock Exchange of India Limited to update their records.

Key Disclosure Details

The following table summarizes the particulars of the disclosure:

Particulars	Details
Promoter Name	Omkar Herlekar
Company	Lasa Supergenerics Limited
Financial Year Ended	March 31, 2026
New Encumbrance	None
Regulation	SEBI (SAST) Regulations, 2011
Filing Date	April 7, 2026

The confirmation of no new encumbrances provides transparency to shareholders regarding the promoter's financial commitments and the potential risk of pledge invocation. The document was signed by Omkar Herlekar, citing his Director Identification Number (DIN) as 01587154. A copy of the disclosure was also forwarded to the members of the Audit Committee of Lasa Supergenerics Limited for their information.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.27%	-6.57%	-4.00%	-21.71%	-48.56%	-89.89%

Lasa Supergenerics Limited has disclosed its related party transactions for the quarter and year ended March 31, 2026. The filing, submitted to the stock exchanges on May 29, 2026, details payments made to directors, key managerial personnel, and a foundation connected to the company. The total value of transactions executed during the reporting period amounted to ₹35.36 lakh, against an approved limit of ₹618 lakh by the audit committee.

The disclosures were made in compliance with Regulation 23(9) of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The transactions primarily cover remuneration, sitting fees, and donations. The company’s Chairman and Managing Director, Omkar Herlekar, received ₹3 lakh, while Whole Time Directors Umesh Pawar, Prathmesh Chalke, and Ganesh Potdar received ₹1.49 lakh, ₹4.63 lakh, and ₹0.30 lakh respectively.

Breakdown of Transactions

The following table summarizes the key related party transactions reported for the period:

Related Party	Relationship	Transaction Type	Approved Value (₹ lakh)	Reporting Period Value (₹ lakh)
Mr. Omkar Herlekar	Promoter-Managing Director	Directors Remuneration	100	3.00
Mr. Umesh Pawar	Whole Time Director	Directors Remuneration	100	1.49
Mrs Mitti Jain	Company Secretary	Remuneration	100	5.59
Dr Omkar Herlekar Foundation	Common Director	Donation Given	200	15.50
Mr. Prathmesh Chalke	Whole Time Director	Directors Remuneration	8	4.63

Independent Directors received sitting fees for their participation in board meetings. Ms. Ekta Gurnasinghani, Mr. Hardesh Tolani, and Ms. Manali Bhagtani each received ₹0.75 lakh. Other independent directors, including Ms. Ajay Sukhwani, Mr. Yogesh Hari Ughada, Mr. Pravin Gadalya Lachake, Mr. Ketan Bhau Songal, and Ms. Rekha Hemant Wakh, received amounts ranging from ₹0.10 lakh to ₹1.00 lakh.

The Chief Financial Officers (CFOs), Mr. Ravi Shankar Kabra and Ms. Varsha Joshi, were remunerated ₹0 and ₹1.20 lakh respectively during the quarter. The audit committee had previously approved a total remuneration limit of ₹30 lakh for Mr. Kabra and ₹8 lakh for Ms. Joshi.